{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"To evaluate the pharmacodynamic effects of AZD1775 drugs when administered in combination with radiotherapy and concurrent cisplatin. Pharmacodynamic biomarkers will include: pCDC2, Ki67, γH2AX, pH3, and CC3. Associations between pharmacokinetic data with toxicity profiles will be performed primarily using descriptive statistics; however, logistic regression may be used if warranted.","groups":[{"description":"Patients undergo external beam radiation therapy on days 1-5, receive AZD1775 PO on days 1, 3, and 5, and receive cisplatin IV over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.","id":"OG000","title":"Treatment (Radiation Therapy, AZD1775 3 Days/Week, Cisplatin) Dose Level 1"},{"description":"Patients undergo external beam radiation therapy on days 1-5, receive AZD1775 PO on days 3 and 5, and receive cisplatin IV over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.","id":"OG001","title":"Treatment (Radiation Therapy, AZD1775 2 Days/Week, Cisplatin) Dose Level -1"}],"populationDescription":"Not analyzed as samples were not collected, therefore no data are available.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Pharmacodynamic Effects of AZD1775 in Combination With RT and Concurrent Cisplatin","type":"SECONDARY"}